Skip to main content

DETECT research study

We’re sorry! We’re no longer enrolling participants in our DETECT study. You can still learn about the study by reading below. 

What is DETECT?

Detecting Cancers Earlier Through Elective Mutation-Based Blood Collection and Testing (DETECT) is a research study that is trying to understand how well a blood test works for finding cancer. DETECT uses a research marker panel blood test to look for tumor DNA by checking for 15 genes and look for abnormally high levels of 10 protein markers. 

How many people were recruited for DETECT?

  • Enrollment target: 10,000 patients
  • Current enrollment: 10,006 (we met our target enrollment goal in May 2019)

Where did this study take place?

  • Geisinger Bloomsburg Hospital, Professional Building
  • Geisinger Medical Center (Danville, PA)
  • Geisinger Precision Health Clinic (Forty-Fort, PA)
  • Geisinger Grays Woods (Port Matilda, PA)
  • Geisinger Mount Pocono
  • Geisinger Lewistown
  • Geisinger Tunkhannock
  • Miller Center (Lewisburg, PA)
  • Geisinger Hazleton
  • Tiadaghton Health Center (Lock Haven, PA)
  • Geisinger South Williamsport
  • Geisinger Pottsville
  • Geisinger South Wilkes Barre
  • Geisinger Shamokin Hospital
  • Scranton, PA

What is the study looking at in my blood?

DETECT is looking at circulating tumor DNA and protein markers. Normal cells in your body shed DNA into your bloodstream when they die. Sometimes, cancer cells shed DNA into the bloodstream, too. This is called circulating tumor DNA (ctDNA). We are looking at about 15 genes that may be found in the blood when cancer cells shed DNA. Some cancers might also cause levels of certain proteins in the blood to rise above normal. We are measuring about 10 protein markers that are in the blood. 

If I have more questions, who do I contact?

For more information about the study, call our DETECT study team at 570-387-2154.